UK-based multinational pharmaceutical company Hikma Pharmaceuticals plc (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) announced on Monday that it has introduced the first-of-its-kind, ready-to-use vancomycin premix with room-temperature stability under the brand name TYZAVAN (vancomycin injection, USP) in the United States.

TYZAVAN is offered in pre-filled ready-to-use bags designed to help hospitals, pharmacists, doctors, and nurses treat patients faster, more easily, and with reduced risk.

TYZAVAN, a glycopeptide antibacterial, is indicated for the treatment of infections such as septicaemia; infective endocarditis; skin and skin structure infections; bone infections; and lower respiratory tract infections.

According to Hikma, TYZAVAN is the only FDA-approved vancomycin injection available for adults and paediatric patients (aged one month and older) that can be stored at room temperature and used immediately, eliminating the need for compounding, thawing, assembly or activation to streamline preparation and accelerate treatment.